CR20190594A - Receptores de células t novedosos, e inmunoterapia usando los mismos - Google Patents

Receptores de células t novedosos, e inmunoterapia usando los mismos

Info

Publication number
CR20190594A
CR20190594A CR20190594A CR20190594A CR20190594A CR 20190594 A CR20190594 A CR 20190594A CR 20190594 A CR20190594 A CR 20190594A CR 20190594 A CR20190594 A CR 20190594A CR 20190594 A CR20190594 A CR 20190594A
Authority
CR
Costa Rica
Prior art keywords
spink2
antigen recognizing
recognizing constructs
taa
tcr
Prior art date
Application number
CR20190594A
Other languages
English (en)
Inventor
Leonie Alten
Sebastian Bunk
Dominik Maurer
Claudia Wagner
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CR20190594A publication Critical patent/CR20190594A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a constructos reconocedores de antígeno dirigidos contra antígenos asociados a tumores (TAA), en particular contra el TAA denominado inhibidor de serina peptidasa Kazal de tipo 2 (SPINK2). La invención proporciona, en concreto, moléculas novedosas basadas en un nuevo receptor de células T (TCR) que son selectivas y específicas hacia el antígeno de la invención que es expresado por tumores. El TCR de la invención, así como los fragmentos de unión con el antígeno SPINK2 y que derivan del mismo, están destinados al uso en el diagnóstico, el tratamiento y la prevención de enfermedades tumorales que expresan el SPINK2. Además, se proporcionan ácidos nucleicos que codifican los constructos reconocedores del antígeno de la invención, los vectores que comprenden esos ácidos nucleicos, las células recombinantes que expresan los constructos reconocedores del antígeno, y las composiciones farmacéuticas que comprenden los compuestos de la invención.
CR20190594A 2017-06-30 2018-06-28 Receptores de células t novedosos, e inmunoterapia usando los mismos CR20190594A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527844P 2017-06-30 2017-06-30
DE102017114737.3A DE102017114737A1 (de) 2017-06-30 2017-06-30 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
PCT/EP2018/067380 WO2019002444A1 (en) 2017-06-30 2018-06-28 NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME

Publications (1)

Publication Number Publication Date
CR20190594A true CR20190594A (es) 2020-03-02

Family

ID=64662173

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190594A CR20190594A (es) 2017-06-30 2018-06-28 Receptores de células t novedosos, e inmunoterapia usando los mismos

Country Status (20)

Country Link
US (4) US10590194B2 (es)
EP (1) EP3645573B1 (es)
JP (1) JP7235316B2 (es)
KR (1) KR20200023288A (es)
CN (1) CN110753705A (es)
AR (1) AR112604A1 (es)
AU (1) AU2018293322A1 (es)
BR (1) BR112019025323A2 (es)
CA (1) CA3067757A1 (es)
CL (1) CL2019003885A1 (es)
CO (1) CO2020000357A2 (es)
CR (1) CR20190594A (es)
DE (1) DE102017114737A1 (es)
IL (1) IL271751A (es)
MA (1) MA49503A (es)
MX (1) MX2019015742A (es)
PE (1) PE20200337A1 (es)
SG (1) SG11201911437VA (es)
TW (1) TWI727182B (es)
WO (1) WO2019002444A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230343A1 (es) 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
CA3203118A1 (en) 2020-12-31 2022-07-07 Gagan BAJWA Cd8 polypeptides, compositions, and methods of using thereof
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
AU5244499A (en) * 1998-07-31 2000-02-21 Diagnostic Products Corporation Polynucleotide encoding an autoantigen associated with endometriosis
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
EP2116596A4 (en) * 2007-03-05 2010-04-07 Int Inst Cancer Immunology Inc L-CELL RECEPTOR GENE SPECIFIC TO A CANCER ANTIGEN, PEPTIDE CODED BY THE GENE AND THEIR USE
DK2883954T3 (da) 2012-08-08 2020-09-28 Daiichi Sankyo Co Ltd Peptidbibliotek og anvendelse deraf
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
ES2819256T3 (es) * 2014-11-05 2021-04-15 Genentech Inc Métodos para producir proteínas bicatenarias en bacterias
EP3156067A1 (en) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
GB201520567D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers

Also Published As

Publication number Publication date
KR20200023288A (ko) 2020-03-04
CN110753705A (zh) 2020-02-04
SG11201911437VA (en) 2020-01-30
US10723796B2 (en) 2020-07-28
US10590194B2 (en) 2020-03-17
JP2020529830A (ja) 2020-10-15
US20210388079A1 (en) 2021-12-16
WO2019002444A9 (en) 2019-03-14
IL271751A (en) 2020-02-27
AU2018293322A1 (en) 2020-01-16
CA3067757A1 (en) 2019-01-03
TW201904989A (zh) 2019-02-01
DE102017114737A1 (de) 2019-01-03
US20200140540A1 (en) 2020-05-07
US20190256590A1 (en) 2019-08-22
MA49503A (fr) 2020-05-06
CO2020000357A2 (es) 2020-01-31
CL2019003885A1 (es) 2020-05-29
TWI727182B (zh) 2021-05-11
US20190002556A1 (en) 2019-01-03
MX2019015742A (es) 2020-02-20
WO2019002444A1 (en) 2019-01-03
PE20200337A1 (es) 2020-02-14
EP3645573A1 (en) 2020-05-06
AR112604A1 (es) 2019-11-20
EP3645573B1 (en) 2024-10-16
US11111294B2 (en) 2021-09-07
JP7235316B2 (ja) 2023-03-08
BR112019025323A2 (pt) 2020-06-23

Similar Documents

Publication Publication Date Title
MX2019015742A (es) Receptores de celulas t novedosos, e inmunoterapia usando los mismos.
MX2022015821A (es) Nuevos receptores de celulas t y usos de los mismos.
MX2019006724A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
MX2023003463A (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame.
PH12020550600A1 (en) Novel engineered t cell receptors and immune therapy using the same
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
MX2019001769A (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
PH12019500312A1 (en) T cell receptors and immune therapy using the same
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
PH12019500571A1 (en) Anti-pd-1 antibodies
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
EA202090712A1 (ru) Новые полученные методами генной инженерии t-клеточные рецепторы и иммунная терапия с их использованием
PH12019501263A1 (en) Novel t cell receptors and immune therapy using the same
MY195101A (en) Novel T Cell Receptors and Immune Therapy Using the Same
EA201991139A1 (ru) Новые т-клеточные рецепторы и иммунотерапия с их применением
EA201992583A1 (ru) Новые t-клеточные рецепторы и иммунотерапия с их применением
EA201992002A1 (ru) Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением
EA201990488A1 (ru) Новые t-клеточные рецепторы и иммунотерапия с их применением